Nachman most recently served as company group chair within the Johnson & Johnson Medical Devices (now MedTech) business. He also joined the board of transcatheter aortic valve replacement technology developer JenaValve in September.
“I am thrilled that Shlomi has joined the board of directors,” said Michael Carrel, president and CEO of AtriCure. “He is one of the most well-respected leaders in the medical device space, having led Johnson & Johnson’s medical device business through a period of unprecedented growth. His experience in the AFib market will be invaluable as we continue our mission of healing the lives of those affected by this global epidemic.”
More about new AtriCure board member Shlomi Nachman
With more than 25 years in the medical device industry, Nachman has a long history at J&J. He served as company group chair of cardiovascular and specialty solutions and vision groups within the Medical Devices business. Additionally, Nachman led a portfolio of diverse businesses there, including electrophysiology, neurovascular intervention, ENT, breast aesthetics, optometry and ophthalmology.
Before those roles, Nachman also held the post of worldwide president of Biosense Webster and Cordis.
AtriCure develops technology for treating AFib, left atrial appendage (LAA) management and post-operative pain management. Nachman said that, during his time at Biosense Webster, he “got to know” the challenges facing the treatment of AFib.
“There is an abundance of untapped opportunity and AtriCure is at the forefront of treating a segment of the market that includes patients who are significantly underserved,” Nachman said. “I have done extensive diligence on the company’s business, prospects, and end user markets, and believe them to be significantly underpenetrated.
“The unique combination of world-class products, and a foundation of clinical science to support safety and efficacy, has the company poised to continue its leadership position and execute on a long runway of growth.”
